Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Other Accumulated Expenses (2021 - 2025)

Universe Pharmaceuticals' Other Accumulated Expenses history spans 5 years, with the latest figure at $54.7 million for Q3 2025.

  • For Q3 2025, Other Accumulated Expenses fell 62.88% year-over-year to $54.7 million; the TTM value through Sep 2025 reached $54.7 million, down 62.88%, while the annual FY2025 figure was $54.7 million, 62.88% down from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $54.7 million at Universe Pharmaceuticals, down from $147.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $147.4 million in Q3 2024 and bottomed at $52263.0 in Q3 2022.
  • The 5-year median for Other Accumulated Expenses is $131045.0 (2023), against an average of $40.5 million.
  • The largest annual shift saw Other Accumulated Expenses surged 112404.1% in 2024 before it crashed 62.88% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $105212.0 in 2021, then tumbled by 50.33% to $52263.0 in 2022, then soared by 150.74% to $131045.0 in 2023, then soared by 112404.1% to $147.4 million in 2024, then plummeted by 62.88% to $54.7 million in 2025.
  • Per Business Quant, the three most recent readings for UPC's Other Accumulated Expenses are $54.7 million (Q3 2025), $147.4 million (Q3 2024), and $131045.0 (Q3 2023).